Trevi Therapeutics

1 follower

Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions.

Employees

11-50

Links


Org chart

Jennifer Good
President and CEO
Collapse
Thomas Sciascia
Co-Founder, Chief Science Officer
Farrell Simon
Chief Commercial Officer
Katherine Takaki
VP, Global Regulatory Affairs
David Clark
Chief Medical Officer

Board & advisors

David Meeker
Chairman
James Cassella
Chief Development Officer (cdo)
Dominick Colangelo
Board Member
Michael Heffernan
Lead Independent Director
Ed Mathers
Board Member
Anne Vanlent
Member Board Of Directors. Audit Committee Chair